SCHEMBL18193064

SCHEMBL18193064

Cc1cccc2c(=O)c3c(sc4c(=O)c5cccc(NC(=O)C(F)(F)F)c5c(=O)c43)c(=O)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 3/20 0.41
▸ MAPT P10636 2/20 0.41
▸ JAK2 O60674 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ KLK7 P49862 1/20 0.41
▸ PDK1 Q15118 1/20 0.38
▸ PDK2 Q15119 1/20 0.38
▸ PDK3 Q15120 1/20 0.38
▸ PDK4 Q16654 1/20 0.38
▸ ANO1 Q5XXA6 2/20 0.38
▸ PARP14 Q460N5 1/20 0.37
▸ AR P10275 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ ANO2 Q9NQ90 1/20 0.37
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ HIF1A Q16665 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16745425 0.93 TP53 (0.46) TP53MAPTJAK2HTTKLK7
SCHEMBL16747994 0.90 TP53 (0.48) TP53MAPTJAK2HTTKLK7
SCHEMBL16747993 0.90 JAK2 (0.48) TP53MAPTJAK2HTTKLK7
SCHEMBL16745350 0.89 L3MBTL1 (0.43) TP53MAPTJAK2HTTKLK7
SCHEMBL16745360 0.87 L3MBTL1 (0.45) TP53MAPTJAK2HTTKLK7
SCHEMBL16745376 0.87 L3MBTL1 (0.45) TP53MAPTJAK2HTTKLK7
SCHEMBL18193066 0.76 DPP3 (0.45) MAPTHTTLMNAL3MBTL1MEN1
SCHEMBL18193063 0.73 ALDH1A1 (0.36) MAPTCYP1A2CYP3A4KDM4ELMNA
SCHEMBL18193068 0.70 ALDH1A1 (0.38) MAPTCYP1A2CYP3A4KDM4ELMNA
SCHEMBL16747996 0.70 NPY5R (0.45) TP53MAPTSMN1; SMN2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9481662-B2 Seriniquinones, melanoma-specific anticancer agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-11-01 — — US disclosed
Send feedback